SmartCelleTM – Enabling Delivery
SmartCelle dynamic micelles reversibly bind highly insoluble drugs like TA-A001 increasing their solubility many thousand fold while retaining a viscosity close to that of water. Small volume, high concentration injectable solutions are produced which may be terminally filtered or sterilized to generate simple intravenous administration. Once injected the micelles dissociate releasing their payload directly into the blood. Binding of SmartCelle micelles to blood proteins can also increase circulation time.
The small size (30nm) and neutral charge of SmartCelle micelles makes them ideal carriers of drugs across the tear-film and mucins of the eye allowing direct access to the corneal epithelium. Entrapment in the corneal glycocalyx also promotes sustained drug delivery. Access to the rear of the eye via the conjunctiva –scleral route is also enhanced.
Spray-dried micellar formulations allow intra-nasal delivery and the possibility of direct access to the CNS.
Safety and Tolerability
SmartCelle micelles comprise copolymers of two FDA approved excipients for intravenous administration. The low molecular weight and biodegradability of SmartCelle polymers allows predominantly renal clearance after intravenous administration where bolus injections of over 300mg/kg have been well tolerated in animal models.
TALLC issues new Corporate Presentation
Dr. Damon Smith at Biotech Show Case
TALLC at the Ophthalmology Innovation Summit
TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001
Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001
© TALLC Inc. 2020